Testing Bipolar Androgen Therapy with Darolutamide to Delay Metastasis in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Led by Australian and New Zealand Urogenital and Prostate Cancer Trials Group · Updated on 2026-04-24
69
Participants Needed
12
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of cyclical testosterone and darolutamide in adults with non-metastatic castration-resistant prostate cancer nmCRPC. The study aims to see if this combination can delay the time it takes for the cancer to spread to other parts of the body or lead to death. This research involves patients who have rising prostate-specific antigen PSA levels despite treatment with darolutamide but show no metastatic disease on conventional imaging.
Participants will continue to receive androgen deprivation therapy using LHRH agonists or antagonists. They will also receive intramuscular injections of testosterone enanthate on day 1 of each 56-day cycle, with darolutamide taken orally at 600 mg twice daily from days 29 to 56 of each cycle. These treatments will continue until disease progression, unacceptable side effects, death, withdrawal, or study termination. Standard care medications like LHRH agonistsantagonists and darolutamide are provided through usual healthcare channels.
Throughout the study, participants will undergo blood tests, scans including whole body bone scans and CT scans, and complete quality of life questionnaires. The main outcome measured is metastasis-free survival, tracked every 8 weeks for approximately four years. Safety and tolerability, PSA response, quality of life, hormone levels, and bone health markers will also be monitored regularly during the study, which may last around two years for some assessments.
CONDITIONS
Brief Title
Working Out M0 Bipolar Androgen Therapy
Research Team
A
Antoinette Fontela, BSc
J
Jennifer Thompson, BSc
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Lead Sponsor
Bayer
Collaborating Sponsor
Who Can Participate
Age: 18Years +
MALE
Eligibility Criteria
You may qualify if you...
Histologically confirmed adenocarcinoma of the prostate
18 years of age or older
ECOG performance status 0-1
PSA progression on darolutamide with three rising PSA levels at least 1 week apart despite castrate testosterone level
AJCC stage M0 on conventional imaging (WBBS and CT scan)
Previous PSMA PET showing only M1 disease now M0 CRPC after more than 18 months of ADT plus darolutamide are eligible
Pelvic lymph nodes up to 2cm in short axis permitted
PSA greater than 1.0 ng/mL during screening
Serum testosterone less than 1.7 nmol/L and on LHRH agonist or antagonist
Adequate bone marrow function (platelets >100 x 10^9/L, ANC >1.5 x 10^9/L, hemoglobin >90)
Adequate liver function (ALT or AST less than 2.5 times upper limit of normal, bilirubin less than 1.5 times upper limit)
Adequate renal function (creatinine less than 1.5 times upper limit)
Willingness and ability to follow study requirements including treatment and timing
You will not qualify if you...
Life expectancy less than 3 months
Neuroendocrine or small cell prostate cancer on any prior tissue sample
Metastatic prostate cancer on conventional imaging at any point (except pelvic nodes up to 2cm)
Prior treatment with enzalutamide, abiraterone, apalutamide, or cytotoxic chemotherapy, except certain cases with prior docetaxel stopped at least 12 months before study
Current or prior cardiac or thromboembolic risk factors including recent myocardial infarction or unstable angina
Uncontrolled or symptomatic cardiac disease or significant co-morbidities increasing cardiovascular risk
Another malignancy diagnosed within 2 years before registration, except certain treated skin cancers or low-risk malignancies
Concurrent illness that would prevent safe participation
Planned ongoing drug interactions that cannot be managed
Radiation therapy within 4 weeks prior to study entry, with some exceptions for SBRT to PSMA PET only disease prior to enrollment if continuing darolutamide treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Repeated 56-day cycles until evidence of metastatic disease or discontinuation
Participants receive cyclical treatment with intramuscular testosterone enanthate and oral darolutamide in 56-day cycles. They continue medical or surgical castration during treatment.
Visits every 2 weeks for the first 8 weeks, then every 4 weeks until end of treatment
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study of 177Lu-PSMA as an Additional Treatment for High and Very High Risk Prostate Cancer After Radiation and Hormone Therapy
Phase 1b Study of 177Lu-PSMA-617 With Liver-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Using 18F-PSMA-1007 PET-CT to Guide Targeted Focal Therapy for MRI-Invisible Prostate Cancer
A Prospective Phase II Study Evaluating PET-Directed Treatment in Men with Localized Intermediate-Risk Prostate Cancer
Evaluation of 18F-PSMA-1007 PETCT Imaging Safety and Effectiveness in Adult Men with Prostate Cancer
Combining One MR-Guided HDR Brachytherapy and One SABR Treatment
for Favorable Risk Prostate Cancer
in a Phase 23 Study
Study of 4-Aminopyridine to Improve Nerve Recovery After Robot-Assisted Radical Prostatectomy in Men with Prostate Cancer
Phase III Study of 64Cu-GRIP B PET Imaging for Detecting Granzyme B in Adults with Advanced Genitourinary and Other Solid Tumors
Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 PETCT Scans for Detecting Primary Prostate Cancer in Men
Using 68Ga-PSMA PETMRI and mpMRI to Detect Prostate Cancer in Men Aged 40 to 85
Observational Study to Compare Diagnostic Accuracy and Follow-Up Outcomes
PETCT Imaging Using 68Ga-RM26-RGD to Detect Breast, Brain, and Prostate Tumors with GRPR and v3 Receptors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
WOMBAT (ANZUP 2201): A Phase 2, Single-arm Study of Bipolar Androgen Therapy in Patients with Nonmetastatic Castration-resistant Prostate Cancer with Prostate-specific Antigen Progression on Darolutamide.
Barak Talmor, Carole A Harris, Christopher Gianacas...